Donate Help Contact The AHA Sign In Home
American Heart Association
Circulation
Search: search_blue_button Advanced Search
Circulation. 1999;100:1236-1241

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Morgan, D. C.
Right arrow Articles by McManus, B. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Morgan, D. C.
Right arrow Articles by McManus, B. M.
Related Collections
Right arrow Animal models of human disease
Right arrow Other diagnostic testing
Right arrow CV surgery: transplantation, ventricular assistance, cardiomyopathy

(Circulation. 1999;100:1236-1241.)
© 1999 American Heart Association, Inc.


Basic Science Reports

New Method for Detection of Heart Allograft Rejection

Validation of Sensitivity and Reliability in a Rat Heterotopic Allograft Model

David C. Morgan, PhD; Janet E. Wilson, BSc, MT(ASCP); Calum E. MacAulay, PhD; Nicholas B. MacKinnon, BSc, AScT; Jennifer A. Kenyon, BSc; Paul S. Gerla, BSc; Chunming Dong, MD, PhD; Haishan Zeng, PhD; Peter D. Whitehead; Christopher R. Thompson, MD, CM; Bruce M. McManus, MD, PhD

From Biomax Technologies, Inc, Vancouver, BC (D.C.M., P.S.G., P.D.W., C.R.T.); Department of Pathology and Laboratory Medicine, St. Paul's Hospital–University of British Columbia, Vancouver, BC (J.E.W., J.A.K., C.D., B.M.M.); Cancer Imaging, BC Cancer Agency, Vancouver, BC (C.E.M., N.B.M., H.Z.); and Division of Cardiology, St. Paul's Hospital, University of British Columbia, Vancouver, BC (C.R.T.).

Correspondence to Bruce M. McManus, MD, PhD, St. Paul's Hospital–University of British Columbia, 1081 Burrard St, Vancouver, BC V6Z 1Y6. E-mail mcmanus{at}interchange.ubc.ca


*    Abstract
up arrowTop
*Abstract
down arrowIntroduction
down arrowAutofluorescence
down arrowMethods
down arrowResults
down arrowDiscussion
down arrowReferences
 
Background—Patients with inflammatory heart muscle diseases would benefit from a safe, convenient, rapidly performed diagnostic technique with real-time results not involving tissue removal. We have performed a detailed evaluation of detection of heart allograft rejection by autofluorescence in a heterotopic abdominal rat heart allograft model ex vivo.

Methods and Results—Recipient rats with allograft (Lewis to Fisher 344; n=71) and isograft (Lewis to Lewis; n=33) hearts, treated with cyclosporine or untreated, were killed at days 2, 4, 7, 14, 21, 28, and 56 after transplant. Nontransplant controls with (n=24) or without (n=24) immunosuppressive therapy were also studied. When the rats were killed, autofluorescence spectra were acquired under blue-light excitation from midtransverse ventricular sections of native and transplanted hearts. Corresponding sections were then evaluated pathologically by a modified International Society for Heart and Lung Transplantation (ISHLT) grading schema. The spectral differences between rejecting and nonrejecting hearts were quantified by linear discriminant functions, producing scores that decreased progressively with increasing severity of tissue rejection. Mean±SD discriminant function scores were 2.9±1.6, 1.8±2.2, -0.1±2.8, -1.2±2.3, and -2.3±3.0 for isografts and allograft ISHLT grades 0, I, II, and III, respectively (Spearman rank-order correlation -0.6; P<0.001, test for trend). Cyclosporine had no detectable effect on the spectra.

Conclusions—The correlation between changes in autofluorescence spectra and ISHLT rejection grade strongly supports the possibility of catheter-based, fluorescence-guided surveillance of rejection.


Key Words: transplantation • rejection • biopsy • spectroscopy


*    Introduction
up arrowTop
up arrowAbstract
*Introduction
down arrowAutofluorescence
down arrowMethods
down arrowResults
down arrowDiscussion
down arrowReferences
 
Amajor challenge in cardiac transplantation is prevention and surveillance of acute graft rejection.1 Maintenance of immunosuppression at the appropriate level to protect an allograft from the alloimmune response requires a reliable method for allograft surveillance and early recognition of acute rejection. Histological grading of the rejection process in endomyocardial biopsy specimens2 3 currently guides antirejection therapy. Many centers perform routine surveillance biopsies up to 18 times in the first year and annually thereafter, in addition to biopsies for clinically suspected rejection. Methods that provide immediate, accurate results with limited invasiveness, reduced risks, and less inconvenience to the patient would be attractive alternatives to the endomyocardial biopsy.4 5 To date, surface and intracardiac ECGs,6 7 echocardiographic parameters including 2D and Doppler measures of systolic and diastolic function,8 9 10 11 and radionuclide imaging including ventriculography and antimyosin imaging,12 13 14 MRI,15 and cytoimmunological monitoring16 17 18 have demonstrated limited predictive accuracy or practicability for monitoring transplant rejection.


*    Autofluorescence
up arrowTop
up arrowAbstract
up arrowIntroduction
*Autofluorescence
down arrowMethods
down arrowResults
down arrowDiscussion
down arrowReferences
 
Spectroscopy typically involves placing a probe in contact with or near a tissue surface and obtaining fluorescence spectra for that single location. Typical biological fluorophores (molecules, cells, or tissue structures that give off fluorescent light when appropriately excited), with specific fluorescence signatures, include tryptophan, NADH, flavins (FAD), collagens, collagen cross-links, elastins, and porphyrins. Autofluorescence spectra obtained from tissue reflect both the spectra of the individual fluorophores present and their modification by adsorptive and dispersive tissue factors.19 20

Excitation wavelength ({lambda}) selection depends both on the efficacy achievable for an intended purpose and on safety. Autofluorescence spectroscopy has been applied in characterization of pathological changes in the lung, gastrointestinal tract, larynx, cervix, skin, and eye,21 22 and tissue autofluorescence induced by blue-light excitation has been effective in the early diagnosis of a variety of cancers.23 24 25 26 27 Characterization of heart and vascular tissue has been attempted mainly with UV excitation, including identification of the sinoatrial and atrioventricular nodal conduction tissue,28 detection of myocardial ischemia,29 monitoring of myocardial redox status,30 and localization of atherosclerotic plaque.31 32 33 Nilsson et al34 used both near-infrared spectroscopy and laser-induced fluorescence to identify various types of cardiac tissue, and Perk et al35 studied fibrosis of the endocardium and myocardium. Two important changes that occur in acutely rejecting tissue are edema and the infiltration of leukocytes. Increased protein-rich interstitial fluid could cause changes in the autofluorescence response of heart tissue. The autofluorescence properties of most leukocytes under blue-light excitation are not well understood. Eosinophils have a characteristic autofluorescence signature when excited by blue light, primarily due to FAD,36 37 although their role in tissue rejection remains unclear. The absorptive and light-scattering properties of any infiltrating cells should be different from in situ myocytes and would probably affect the autofluorescence signature of heart tissue. Similarly, necrotic or markedly damaged myocytes will likely have different absorptive and scattering properties than viable myocytes.

To the best of our knowledge, a systematic investigation of the autofluorescence properties of tissue inflammation in heart rejection or of the diagnostic potential of autofluorescence spectra in this regard has not been reported. We now present evidence that autofluorescence under blue-light excitation may be useful in grading acute rejection based on studies ex vivo in a heterotopic abdominal rat heart allograft model.38 39


*    Methods
up arrowTop
up arrowAbstract
up arrowIntroduction
up arrowAutofluorescence
*Methods
down arrowResults
down arrowDiscussion
down arrowReferences
 
Rat Heart Transplant Model
With Lewis-to–Fisher 344 allografts and Lewis-to-Lewis isografts, the native heart of the rat receiving the transplant serves as an internal control for the systemic immune environment. Allograft recipients and isograft recipients, as well as nontransplant controls, were treated with cyclosporine (2.5 mg · kg-1 · d-1) via subcutaneous injection for 7 days or left untreated (TableDown). All animal experiments were approved by the University of British Columbia Committee on Animal Care (protocol number A96-0322) in accordance with the Canadian Council on Animal Care. All rats were acclimatized for 1 week and weighed 200 to 225 g at the time of surgery. The technical details of the transplant procedure are well described elsewhere.38 39


View this table:
[in this window]
[in a new window]
 
Table 1. Experimental Design

Euthanasia and Tissue Triage Protocol
Rats were killed by carbon dioxide narcosis, and the native and transplanted hearts were removed, sectioned, and processed. A first most-basal ventricular bread-loaf section (2 mm thick) was frozen in OCT embedding medium. A second ventricular bread-loaf section (4 to 6 mm thick) was removed, the ventricles were opened anteriorly, and autofluorescence spectra were acquired every 5 mm along all endocardial and epicardial surfaces. The autofluorescence probe was placed perpendicular to the endocardial or epicardial surface to mimic the way tissue is taken with an endomyocardial bioptome. Once all autofluorescence measurements were completed on a given bread-loaf section, it was processed for histopathological review.

Spectral Measurements
The optical probe and spectroscopy systems used to acquire the autofluorescence spectra are represented in Figure 1Down. The 200-µm-diameter fiber in the center of the probe tip illuminated the tissue with 442-nm excitation light from an HeCd laser. Autofluorescence light emitted by the tissue was collected by six 200-µm-diameter optical fibers surrounding the central excitation fiber. Signals from the collection fibers were first filtered (475-nm long-pass filter) to remove any reflected excitation light and then relayed to a spectrometer. The resulting autofluorescence spectra were calibrated for the light response of the system, normalized to 1 at their maximum intensity, and then binned into 2-nm-wavelength intervals in the range of 480 to 800 nm.



View larger version (25K):
[in this window]
[in a new window]
 
Figure 1. Optical system for detection of tissue rejection.

A contour plot based on a Monte Carlo simulation of the sensitivity of the probe to the tissue area (1000 µm diameter, 650 µm depth) near its tip is shown in Figure 2ADown; the illumination fiber is at the origin. The optical properties used for these simulations40 were estimated on the basis of dog myocardium41 values. The contour plot shows that the largest contribution comes from an area centered at {approx}200 µm in depth and extending radially, {approx}75 µm from the center of the probe. The dashed boxes represent the tissue regions that account for 50% and 90% of the signal. The 90% box is roughly 700 µm in diameter and extends {approx}550 µm below the tissue surface. A breakdown of the contribution to the total signal from various depths in 50-µm increments demonstrates that the largest contributions come from the 150-to-200 µm and 200-to-250-µm-deep regions (Figure 2BDown).



View larger version (41K):
[in this window]
[in a new window]
 
Figure 2. A, Contour plot from Monte Carlo calculation of the sensitivity of the probe to the tissue region near its tip. The 200-µm excitation fiber is at the origin, and there is a 50-µm gap between it and the six 200-µm-diameter collection fibers (to account for the cladding and coating of fibers). Colors code the relative sensitivities. Dashed boxes show areas that account for {approx}50% or 90% of the signal. B, Histogram showing contribution to total signal derived from various depths at 50-µm increments. Largest contributions come from tissue area 150 to 250 µm from probe.

Histopathological Evaluation
For each rat, 5-µm sections from the native and transplant hearts were cut perpendicular to the endocardium/epicardium, placed on a single glass slide, stained with hematoxylin and eosin, marked to identify the sites of optical measurements, and scored at these sites by use of a modified International Society for Heart and Lung Transplantation (ISHLT) grading system.2 The graders were blinded as to the precise nature of the heart (native, isograft, or allograft), time interval from transplant to euthanasia, treatment group, and spectroscopic results. The modified ISHLT grading system included scores as follows: 0, no rejection; I, IA, and IB, mild; II, moderate; and IIIA, IIIB, and IV, severe. ISHLT grade IA and IB spectra were amalgamated into the single grade I and grade IIIA and IIIB spectra were similarly combined because the A and B designations refer to focal (or multifocal) and diffuse inflammation, respectively, and not to a difference in severity at a given numerical grade. In utilizing these slight modifications of the ISHLT grading system, we also recognize the difference in evaluating human heart biopsy samples versus whole rat hearts.

Data Analysis
To discriminate between 2 groups of autofluorescence spectra on the basis of spectral shape, a full, forward, and backward stepwise linear discriminant function (DF) analysis42 43 was performed. This analysis was designed to pick an optimal set of points along the spectral curve that, when combined as a linear weighted sum, generate a score that distinguishes between the groups:

In the above equation, c0 is a constant, ci values are coefficients, and I({lambda}i) is the autofluorescence intensity at wavelength {lambda}i. In the present report, we will refer to the foregoing process as "training" a linear DF. The DF is then used to score (or test) any other spectra.

The first step was to remove from the analysis set in an unbiased fashion those spectra (n=118) that had clearly identifiable spectral features related to artifacts or blood absorption by use of a linear DF analysis. The remaining spectra (n=1354), largely free of blood absorption effects, were then grouped and analyzed by linear DF analysis to assess the correlation between the histopathological grades and spectral changes.


*    Results
up arrowTop
up arrowAbstract
up arrowIntroduction
up arrowAutofluorescence
up arrowMethods
*Results
down arrowDiscussion
down arrowReferences
 
Photomicrographs from a control heart and representative transplant hearts with modified ISHLT grades 0, I, II, and III rejection and correspondent autofluorescence spectra are shown in Figure 3Down. Rejection caused a shift of the main peak to longer wavelengths, as well as an increase in spectral intensity of longer wavelengths relative to the intensity of the main peak. In addition, the distinct "bump" at 600 nm in the control spectrum disappeared in rejecting hearts.



View larger version (87K):
[in this window]
[in a new window]
 
Figure 3. a, Illustrative autofluorescence spectra with corresponding histological features in myocardium of (b) control Lewis rat, (c) allograft with no rejection, (d) allograft with mild rejection, (e) allograft with moderate rejection, and (f) allograft with severe rejection. Lined box (in b) demarcates area of an average endomyocardial biopsy fragment.

There was no statistical difference between the average spectra of nontransplant controls treated or not treated with cyclosporine (Figure 4Down). Thus, cyclosporine itself did not contribute to heart tissue autofluorescence and had no apparent effect that could obscure spectral changes of interest, those associated with inflammation or injury due to rejection.



View larger version (23K):
[in this window]
[in a new window]
 
Figure 4. Averaged spectra from control rats without cyclosporine treatment versus those from rats treated with cyclosporine. The tissue autofluorescence signal is not affected by cyclosporine.

To correlate autofluorescence spectra with tissue rejection severity, the spectra were separated into groups corresponding to modified ISHLT grades 0 (n=180), I (n=223), II (n=69), and III (n=29). DF analysis was performed with grade 0 and grade III used as the training set, and a DF with wavelength values of 480, 496, 504, 518, and 522 nm was generated. These wavelengths encompass the visually apparent position and shape changes in the main peak of the autofluorescence spectra. This DF was then used to score spectra from native (n=618) and control hearts (n=236), as well as those grafts with a full range of rejection grades (Figure 5Down). Increasing tissue rejection severity was accompanied by a clear progression of decreasing DF scores. Each successive modified ISHLT grade (0, I, and II) is different (Student-Newman-Keuls [SNK] test, P<0.01). The mean DF score for modified ISHLT grade II rejection was higher than that of grade III (SNK test, P=0.06). To test the strength of correlation between the modified ISHLT grade and DF score, we calculated the Spearman rank-order correlation coefficient, RS, based on all grade 0 spectra (including both allograft and isograft) being assigned a value of 0 and grades I, II, and III being assigned values of 1, 2, and 3, respectively. The result was RS=-0.6, reflecting a highly significant correlation (P<0.001). It should be emphasised that the DF was trained only on hearts with ISHLT grade 0 and grade III. Thus, control hearts, native hearts, and grade I and II groups provided genuine tests of the DF performance.



View larger version (24K):
[in this window]
[in a new window]
 
Figure 5. DF scores of autofluorescence spectra classified by a DF trained on tissue samples with modified ISHLT grade 0 and grade III rejection. a, 95% of tissue spectra in this group have DF scores below top of bar extending upward from box. Top of box denotes 75% level, middle of box is 50% level, bottom of box is 25% level, and bottom of bar below box is 5% level. No statistical distributions have been used to model the data, and therefore bars extending above and below the box do not represent SDs. b, **Adjacent groups are statistically different (P<0.01, SNK test). DF scores from (c) native heart tissue of animals with isograft hearts in their abdomens; (d) native heart tissue of animals with allograft hearts in their abdomens undergoing only mild rejection (ISHLT 0, I); (e) native heart tissue of animals with allograft hearts in their abdomens undergoing moderate to severe rejection (ISHLT II, III); (f) isograft transplant tissue sites showing no evidence of rejection (ISHLT 0); (g) allograft transplant tissue sites showing no evidence of rejection (ISHLT 0); (h) allograft transplant tissue sites showing evidence of mild rejection (ISHLT I); (i) allograft transplant tissue sites showing evidence of moderate rejection (ISHLT II); and (j) allograft transplant tissue sites showing evidence of moderate to severe rejection (ISHLT III).


*    Discussion
up arrowTop
up arrowAbstract
up arrowIntroduction
up arrowAutofluorescence
up arrowMethods
up arrowResults
*Discussion
down arrowReferences
 
The differences between DF scores derived from autofluorescence spectra of tissue with different grades of rejection are very encouraging. If a mean rejection score of 0.5 is used as the dividing line between grade 0 and grade III, 95% of the grade III spectra can be classified correctly, while only 20% of the grade 0 scores will be misclassified. Subtle differences in DF scores for the various nonrejecting tissue groups are also interesting and have implications for interpretation of the results. None of the sites probed for fluorescence or examined histologically were confounded by perioperative infarcts.

As expected, the DF does not discriminate between controls (unoperated) and native hearts of animals with an isograft (n=88), wherein there is little or no immune response. We categorized native hearts of allograft animals as those from animals whose transplanted hearts had ISHLT grade 0 or only a few grade I sites (n=194) and those whose allografts had sites with ISHLT grades II and III (n=336). The significant difference between the spectra of the native hearts of animals with an isograft and the native hearts of animals with an allograft suggests that the immune response to the allograft has a detectable remote effect on the autofluorescence of the native heart. Moreover, the difference in the native heart DF scores of the 2 allograft groups implies that this immune response is progressive and linked to increasing severity of tissue rejection in the transplanted heart. The spectral difference between ISHLT grade 0 in the isografts (n=85) and native heart of the isograft group is arguably a direct measure of the effect of the unnatural position and surgical manipulation of the abdominal heart. However, there is little or no visible immune response in animals in either of these groups.

The mean DF score of the allograft grade 0 group is slightly below that of the isograft grade 0 group, which is also consistent with a systemic response that affects tissue beyond the rejecting heart. In addition, any imprecision in matching the tissue sampled by the optical probe with that graded by the pathologist could allow tissue samples in the allograft grade 0 group to be influenced by neighboring tissue with slight rejection. Such "neighborhood" effects would slightly alter the average fluorescence score.

It is widely appreciated that rejection, as defined histopathologically, is a very diffuse process. Thus, the likelihood of detecting rejection, when present, has been shown to be 95% when 3 pieces of bioptome-acquired tissue are evaluated microscopically, whereas the likelihood rises to 98% with 4 pieces of tissue.44 45 The grade of rejection in a given biopsy specimen may not reflect the average rejection grade for an entire heart or chamber; however, the potential virtue of the optical interrogative approach is the ability to sample perhaps 4 times as many sites as conventionally sampled by endomyocardial biopsy in a small fraction of the time. Such a larger representation of ventricular myocardium offers a potentially significant advantage in acquiring an accurate mean score of ongoing rejection in a particular heart.

To date, no particular information exists on the discrimination of different types of inflammation in the heart with the optical bioptome. The differentiation of rejection from infection and the injury or inflammation associated with either process also requires more evaluation. Myocardial infections are relatively rare in contemporary patients; however, we will need to know their differentiating optical features. The large number of sampling sites envisaged with the optical bioptome will help to differentiate a more focal inflammatory infectious process from diffuse organ allogenicity. We intend to address these issues in the future in a swine allograft model using dual tissue and optical biopsy sampling. The swine study has already shown the feasibility of obtaining meaningful spectra in a beating heart.

In conclusion, the autofluorescence spectra from rat heart tissue excited by blue light changes consistently as the hearts undergo transplant rejection, and linear DF analysis can distinguish spectra corresponding to the degrees of tissue rejection. ISHLT grade 0 is readily distinguishable by autofluorescence from grade III and is different from grades I and II. Coupled with its capability of extensive and rapid interrogation of the ventricular endomyocardium, the optical method may facilitate a better understanding of the rejection process and may allow targeting of biopsy sites to increase the diagnostic efficiency of endomyocardial biopsy. Identification of human heart allograft rejection currently remains bound to histopathological evaluation; however, the strong relationship between autofluorescence spectra and modified ISHLT rejection grades we have observed thus far in rat allografts suggests a role for fluorescence-based surveillance of rejection. No insurmountable challenges are anticipated with this technique in orthotopic allografts; indeed, fewer difficulties are likely than in the heterotopic swine model.


*    Acknowledgments
 
The authors gratefully acknowledge Biomax Technologies, Inc, for support for this work and recognize grant support from the Heart and Stroke Foundation of British Columbia and Yukon (Dr McManus) and the British Columbia Transplant Society (Dr McManus). The authors thank Dean English, Diane Minshall, and Dr Shuxin Zheng (technical assistance), Anson Chang (database), and Shelley Wood and Josh King (editorial assistance).


*    Footnotes
 
The prototype device and analysis system used in this study was developed by Biomax Technologies, Inc. Drs McManus and MacAulay are consultants to Biomax Technologies, Inc, which also provided financial support for this study.

Received October 19, 1998; revision received May 4, 1999; accepted May 5, 1999.


*    References
up arrowTop
up arrowAbstract
up arrowIntroduction
up arrowAutofluorescence
up arrowMethods
up arrowResults
up arrowDiscussion
*References
 
1. Balk AH, Zondervan PE, van der Meer P, van Gelder T, Mochtar B, Simoons ML, Weimar W. Effect of adopting a new histological grading system of acute rejection after heart transplantation. Heart.. 1997;78:603–607.[Abstract/Free Full Text]

2. Billingham ME, Cary NR, Hammond ME, Kemnitz J, Marboe C, McCallister HA, Snovar DC, Winters GL, Zerbe A. A working formulation for the standardization of nomenclature in the diagnosis of heart and lung rejection: Heart Rejection Study Group: the International Society for Heart Transplantation. J Heart Transplant.. 1990;9:587–593.[Medline] [Order article via Infotrieve]

3. Winters GL, McManus BM. Consistencies and controversies in the application of the International Society for Heart and Lung Transplantation working formulation for heart transplant biopsy specimens: Rapamycin Cardiac Rejection Treatment Trial Pathologists. J Heart Lung Transplant.. 1996;15:728–735.[Medline] [Order article via Infotrieve]

4. Winters GL. The challenge of endomyocardial biopsy interpretation in assessing cardiac allograft rejection. Curr Opin Cardiol.. 1997;12:146–152.[Medline] [Order article via Infotrieve]

5. Carrier M. Noninvasive assessment of cardiac transplant rejection: a critical look at the approach to acute rejection. Can J Surg.. 1991;34:569–572.[Medline] [Order article via Infotrieve]

6. Warnecke H, Schuler S, Goetze HJ, Matheis G, Suthoff U, Muller J, Tietze U, Hetzer R. Noninvasive monitoring of cardiac allograft rejection by intramyocardial electrogram recordings. Circulation. 1986;74(suppl 5, pt 2): III-72–III-76.

7. Everett JE, Palmer MN, Jessurun J, Shumway SJ. Noninvasive diagnosis of cardiac allograft rejection in an orthotopic canine model. Ann Thorac Surg. 1996;62:1337–1340; discussion 1340–1341.[Abstract/Free Full Text]

8. Popp RL, Schroeder JS, Stinson EB, Shumway NE, Harrison DC. Ultrasonic studies for the early detection of acute cardiac rejection. Transplantation.. 1971;11:543–550.[Medline] [Order article via Infotrieve]

9. Mannaerts HF, Simoons ML, Balk AH, Tijssen J, van der Borden SG, Zondervan PE, Mochtar B, Weimar W, Roelandt JR. Pulsed-wave transmitral Doppler do not diagnose moderate acute rejection after heart transplantation. J Heart Lung Transplant.. 1993;12:411–421.[Medline] [Order article via Infotrieve]

10. Ciliberto GR, Mascarello M, Gronda E, Bonacina E, Anjos MC, Danzi G, Colombo P, Frigerio M, Alberti A, De Vita C. Acute rejection after heart transplantation: noninvasive echocardiographic evaluation. J Am Coll Cardiol.. 1994;23:1156–1161.[Abstract]

11. Vion-Dury J, Mouly-Bandini A, Viout P, Sciaky M, Confort-Gouny S, Monties JR, Cozzone P. Early detection of heart transplant rejection using cardiac echography combined with the assay of glycosylated residues in plasma by proton NMR spectroscopy. C R Acad Sci III. 1992;315:479–484.[Medline] [Order article via Infotrieve]

12. Mullins PA, Schofield PM, Dunning J, Scott J, Aravot D, Large S, Cary N, Wallwork J, Stone D. The use of exercise technetium-99m 2-methoxy-isobutyl-isonitrile (99mTc-Sestamibi) perfusion scanning in the detection of acute rejection after cardiac transplantation. J Nucl Biol Med.. 1992;36:2–6.

13. Frist W, Yasuda T, Segall G, Khaw BA, Strauss HW, Gold H, Stinson E, Oyer P, Baldwin J, Billingham M. Noninvasive detection of human cardiac transplant rejection with In-111 antimyosin (FAB) imaging. Circulation. 1987;76(pt II):V-81–V-85.

14. Bocchi EA, Mocelin AO, de Moraes AV, Menegheti C, de Lourdes Higuchi M, Bacal F, Stolf N, Bellotti G, Pileggi F. Comparison between two strategies for rejection detection after heart transplantation: routine endomyocardial biopsy versus gallium-67 cardiac imaging. Transplant Proc.. 1997;29:586–588.[Medline] [Order article via Infotrieve]

15. Doornbos J, Verwey H, Essed CE, Balk AH, de Roos A. MR imaging in assessment of cardiac transplant rejection in humans. J Comput Assist Tomogr.. 1990;14:77–81.[Medline] [Order article via Infotrieve]

16. Grant SC, Lamb WR, Hutchinson IV, Brenchley PE. Serum soluble adhesion molecules and cytokines in cardiac allograft rejection: the Manchester Transplant Cytokine Group. Transpl Immunol.. 1994;2:321–325.[Medline] [Order article via Infotrieve]

17. Fisher PE, Suciu-Foca N, Ho E, Michler RE, Rose EA, Mancini D. Additive value of immunologic monitoring to histologic grading of heart allograft biopsy specimens: implications for therapy. J Heart Lung Transplant.. 1995;14:1156–1161.[Medline] [Order article via Infotrieve]

18. Tugulea S, Ciubotariu R, Colovai AI, Liu Z, Itescu S, Schulman LL, Fisher PE, Hardy MA, Rose EA, Michler RE, Cortesini R, Suciu-Foca N. New strategies for early diagnosis of heart allograft rejection. Transplantation.. 1997;64:842–847.[Medline] [Order article via Infotrieve]

19. Schomacker KT, Frisoli JK, Compton CC, Flotte TJ, Richter JM, Nishioka NS, Deutsch TF. Ultraviolet laser-induced fluorescence of colonic tissue: basic biology and diagnostic potential. Lasers Surg Med.. 1992;12:63–78.[Medline] [Order article via Infotrieve]

20. Zonios GI, Cothren RM, Arendt JT, Wu J, Van Dam J, Crawford JM, Manoharan R, Feld MS. Morphological model of human colon tissue fluorescence [published erratum appears in IEEE Trans Biomed Eng. 1996;43:437]. IEEE Trans Biomed Eng. 1996;43:113–122.

21. Bigio IJ, Mourant JR. Ultraviolet and visible spectroscopies for tissue diagnostics: fluorescence spectroscopy and elastic-scattering spectroscopy. Phys Med Biol.. 1997;42:803–814.[Medline] [Order article via Infotrieve]

22. Alfano R, Katz A. Fluorescence and raman spectroscopy for tissue diagnosis and characterization. In: Kohen E, Hirschberg J, eds. Analytical Use of Fluorescent Probes in Oncology. New York, NY: Plenum Press; 1996:81–89.

23. Palcic B, MacAulay C, Shlien S, Treurniet W, Tezcan H, Anderson G. Comparison of three different methods for automated classification of cervical cells. Anal Cell Pathol.. 1992;4:429–441.[Medline] [Order article via Infotrieve]

24. Lam S, MacAulay C, Hung J, Le Riche J, Profio AE, Palcic B. Detection of dysplasia and carcinoma in situ with a lung imaging fluorescence endoscope device. J Thorac Cardiovasc Surg.. 1993;105:1035–1040.[Abstract]

25. Zeng H, MacAulay C, McLean DI, Palcic B. Reconstruction of in vivo skin autofluorescence spectrum from microscopic properties by Monte Carlo simulation. J Photochem Photobiol B.. 1997;38:234–240.[Medline] [Order article via Infotrieve]

26. Qu J, MacAulay C, Lam S, Palcic B. Optical properties of normal and carcinoma bronchial tissue. Applied Optics.. 1994;33:7397–7405.

27. Panjehpour M, Overholt BF, Vo-Dinh T, Haggitt RC, Edwards DH, Buckley FPR. Endoscopic fluorescence detection of high-grade dysplasia in Barrett's esophagus. Gastroenterology.. 1996;111:93–101.[Medline] [Order article via Infotrieve]

28. Perk M, Flynn GJ, Gulamhusein S, Wen Y, Smith C, Bathgate B, Tulip J, Parfrey NA, Lucas A. Laser induced fluorescence identification of sinoatrial and atrioventricular nodal conduction tissue. Pacing Clin Electrophysiol. 1993;16:1701–1712.[Medline] [Order article via Infotrieve]

29. Horvath KA, Schomacker KT, Lee CC, Cohn LH. Intraoperative myocardial ischemia detection with laser-induced fluorescence. J Thorac Cardiovasc Surg.. 1994;107:220–225.[Abstract/Free Full Text]

30. Renault G, Muffat-Joly M, Polianski J, Hardy RI, Boutineau JL, Duvent JL, Pocidalo JJ. NADH in situ laser fluorimetry: effect of pentobarbital on continuously monitored myocardial redox state. Lasers Surg Med.. 1987;7:339–346.[Medline] [Order article via Infotrieve]

31. Yan WD, Perk M, Chagpar A, Wen Y, Stratoff S, Schneider WJ, Jugdutt BI, Tulip J, Lucas A. Laser-induced fluorescence, III: quantitative analysis of atherosclerotic plaque content. Lasers Surg Med.. 1995;16:164–178.[Medline] [Order article via Infotrieve]

32. Baraga JJ, Rava RP, Taroni P, Kittrell C, Fitzmaurice M, Feld MS. Laser induced fluorescence spectroscopy of normal and atherosclerotic human aorta using 306–310 nm excitation. Lasers Surg Med.. 1990;10:245–261.[Medline] [Order article via Infotrieve]

33. Chaudhry HW, Richards-Kortum R, Kolubayev T, Kittrell C, Partovi F, Kramer JR, Feld MS. Alteration of spectral characteristics of human artery wall caused by 476-nm laser irradiation. Lasers Surg Med.. 1989;9:572–580.[Medline] [Order article via Infotrieve]

34. Nilsson AM, Heinrich D, Olajos J, Andersson-Engels S. Near infrared diffuse reflection and laser-induced fluorescence spectroscopy for myocardial tissue characterisation. Spectrochim Acta A Mol Biomol Spectrosc. 1997;53A:1901–1912.

35. Perk M, Flynn GJ, Smith C, Bathgate B, Tulip J, Yue W, Lucas A. Laser-induced fluorescence emission, I: the spectroscopic identification of fibrotic endocardium and myocardium. Lasers Surg Med.. 1991;11:523–534.[Medline] [Order article via Infotrieve]

36. Weil GJ, Chused TM. Eosinophil autofluorescence and its use in isolation and analysis of human eosinophils using flow microfluorometry. Blood.. 1981;57:1099–1104.[Abstract/Free Full Text]

37. Mayeno AN, Hamann KJ, Gleich GJ. Granule-associated flavin adenine dinucleotide (FAD) is responsible for eosinophil autofluorescence. J Leukoc Biol.. 1992;51:172–175.[Abstract]

38. Adams DH, Tilney NL, Collins JJ Jr, Karnovsky MJ. Experimental graft arteriosclerosis, I: the Lewis-to-F-344 allograft model. Transplantation.. 1992;53:1115–1119.[Medline] [Order article via Infotrieve]

39. Ono K, Lindsey ES. Improved technique of heart transplantation in rats. J Thorac Cardiovasc Surg.. 1969;57:225–229.[Medline] [Order article via Infotrieve]

40. Wang L, Jacques S. Monte Carlo Modeling of Light Transport in Multi-Layered Tissue in Standard C. Houston, Tex: University of Texas, MD Anderson Cancer Center; 1992.

41. Pickering J, Bosman S, Posthumus P, Blokland P, Beek J, van Gemert M. Changes in the optical properties (at 632.8 nm) of slowly heated myocardium. Appl Opt.. 1993;32:367–371.

42. Tatsuoka M. Techniques for Education and Psychological Research. Toronto, Canada: John Wiley & Sons; 1971:157–242.

43. James M. Classification Algorithms. London, UK: William Collins Sons & Co; 1985;127–148.

44. Spiegelhalter DJ, Stovin PGI. An analysis of repeated biopsies following cardiac transplantation. Stat Med.. 1983;2:33–40.[Medline] [Order article via Infotrieve]

45. Zerbe TR, Arena V. Diagnostic reliability of endomyocardial biopsy for assessment of cardiac allograft rejection. Hum Pathol.. 1988;19:1307–1314.[Medline] [Order article via Infotrieve]




This article has been cited by other articles:


Home page
ChestHome page
G. E. Kochiadakis, S. I. Chrysostomakis, M. D. Kalebubas, G. M. Filippidis, I. G. Zacharakis, T. G. Papazoglou, and P. E. Vardas
The Role of Laser-Induced Fluorescence in Myocardial Tissue Characterization : An Experimental In Vitro Study
Chest, July 1, 2001; 120(1): 233 - 239.
[Abstract] [Full Text] [PDF]


This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Morgan, D. C.
Right arrow Articles by McManus, B. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Morgan, D. C.
Right arrow Articles by McManus, B. M.
Related Collections
Right arrow Animal models of human disease
Right arrow Other diagnostic testing
Right arrow CV surgery: transplantation, ventricular assistance, cardiomyopathy